Companion Animal Postoperative Pain Management Therapeutics Market to Grow with a CAGR of 7.00% through 2028
The rise in orthopedic and dental surgeries and a
growing awareness of pet health is expected to drive the Global Companion
Animal Postoperative Pain Management Therapeutics Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Companion
Animal Postoperative Pain Management Therapeutics Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Companion Animal Postoperative Pain Management Therapeutics Market
stood at USD 340.55 million in 2022 and is anticipated to grow with a CAGR of 7.00%
in the forecast period, 2024-2028. This can be attributed to market data and
research. Data and research play a crucial role in driving the growth of the
global companion animal postoperative pain management therapeutics market.
Organizations like the American Medical Association (AMA) monitor trends and
provide reports, as mentioned in the introduction, showcasing the rise in
clinic visits for dogs due to dental problems. Such reports not only shed light
on the evolving needs of the market but also serve as a reference for
stakeholders in the industry, guiding them in the development of innovative
pain management products. Moreover, the global companion animal postoperative
pain management therapeutics market faces challenges due to regulatory
variations in different regions. A trend towards regulatory harmonization is
emerging, which aims to streamline the approval process for new medications
across borders. This trend is expected to expedite the introduction of
innovative pain management solutions.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Companion Animal Postoperative Pain Management Therapeutics Market.”
The market is poised for further growth, driven by
increasing disposable income in both developing and developed nations. For
instance, as outlined in a report from the American Veterinary Medical
Association (AVMA), pet owners in the United States spent approximately USD
15.42 billion on veterinary surgeries in 2017. During the same year, around 20
million dogs underwent surgical procedures, with approximately 5 million of
them experiencing postoperative pain. The rising adoption of Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) is expected to boost the market for therapeutics aimed at
managing postoperative pain in companion animals. This trend is a result of
heightened concerns among pet owners and a decreased reliance on off-label
human pain relievers. The unmet demand for extended-release local anesthetics
for small animals is driving industry players to develop such drugs. For
example, In situ Biologics' AniGel SR demonstrated 72-hour efficacy in pre-clinical
studies for postoperative pain management, pending approval from the U.S. Food
and Drug Administration (FDA), which is expected to contribute to increased
market revenue in the coming years. According to data from the Animal Cancer
Foundation, there were approximately 65 million dogs and 32 million cats in the
U.S. in 2017. The growing number of veterinary hospitals and pet clinics is
propelling the market for therapeutics to manage postoperative pain in
companion animals. As reported by the American Veterinary Medical Association
(AVMA), private practices catering to small animals in the U.S. increased by
14% in 2018. The use of opioids as postoperative pain relievers is
hampered by stringent regulations affecting both human and animal use. In 2014,
about 40% of U.S. veterinarians used to prescribe opioids for perioperative
treatment in animals. In 2017, the U.S. FDA established guidelines for the safe
use of opioids in pet animals, necessitating veterinarians to obtain Drug
Enforcement licenses before prescribing opioids to animals. According to an
AVMA survey, in 2018, 44% of opioids were being misused or abused by pet
owners, and 11% were intentionally harming their pets with opioids. These
factors are expected to constrain the growth of opioids while driving revenue
for other postoperative pain relievers in the near future.
The Global Companion Animal Postoperative Pain
Management Therapeutics Market is segmented into product, animal type, regional distribution, and company.
Based on its product, the NSAIDs category asserted its
dominance in the market in 2022, primarily due to the widespread availability
of these products. These medications are primarily employed to manage
inflammation and post-surgery pain. NSAIDs offer a cost-effective alternative
compared to opioids and anesthetics, which is consequently boosting their
revenue. Prominent examples of frequently used NSAIDs for post-surgical pain
include Rimadyl (Injectable), Metacam, Deramaxx, and Previcox. Market
participants are actively pursuing the development of innovative NSAIDs
tailored for peri-operative pain management. Notably, Elanco secured approval
for Onsior in May 2016, specifically designed for postoperative pain management
following soft tissue surgery in dogs.
The anesthetics segment is anticipated to exhibit
consistent growth throughout the projected period. Lidocaine and bupivacaine
are commonly utilized anesthetics. According to a report from the AVMA, around
5 million dogs experienced post-surgical pain in 2016. The demand for
controlled-release or long-acting local anesthetics is on the rise, as pet
owners increasingly prefer to bring their pets home after surgical procedures.
In 2016, Aratana Therapeutics introduced Nocita, designed for postoperative pain
management, with the capability to effectively alleviate pain for up to 72
hours.
Based on animal type, the Canine sector secured the
largest market share in 2022, primarily due to a notable increase in surgical
procedures. The growing prevalence of chronic ailments in dogs serves as a key
driver for this trend. Surgeries such as dental procedures, hip dysplasia
treatments, cataract operations, wound repairs, and neutering are among the
most frequently performed procedures on dogs, all necessitating postoperative
care. Furthermore, the rising adoption of dogs as companion animals in households
across both developed and developing nations is expected to further stimulate
market growth.
On the other hand, the Feline segment is poised for a
consistent CAGR during the forecast period. This steady growth is attributable
to a growing concern among cat owners regarding the management of postoperative
pain in their feline companions. Additionally, the increase in surgical
interventions performed on cats plays a significant role in propelling this
segment's growth. Common health issues in cats include urinary tract
infections, bladder stones, kidney diseases, dental and ocular problems, and ear
infections. The surge in cat adoption in European and Asian countries is
contributing to this expansion. Notably, in 2018, Europe boasted a feline
population of 102.69 million, surpassing the canine population of 84.91
million. The availability of favorable insurance policies is also projected to
further augment growth within this segment.
Major companies operating in Global Companion
Animal Postoperative Pain Management Therapeutics Market are:
- Zoetis Inc
- Bayer AG
- Merck Animal Health
- Elanco Animal Health Inc
- Norbrook Laboratories Ltd
- Ceva Sante Animale SA
- Dechra Pharmaceuticals PLC
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global companion animal postoperative pain
management therapeutics market is undergoing a transformative phase with a
focus on personalized pain management, advanced pharmaceutical innovations, the
integration of alternative therapies, telemedicine and remote monitoring,
ethical and environmental considerations, regulatory harmonization, and
enhanced pain assessment tools. These upcoming trends promise to provide more
effective, compassionate, and sustainable pain management solutions, ensuring
the well-being and comfort of our beloved companion animals as the industry
evolves to meet their evolving needs,” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Companion Animal Postoperative Pain
Management Therapeutics Market By Product
(NSAIDs, Anesthetics, Opioids, Others), By Animal Type (Canine, Feline), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Companion Animal Postoperative Pain
Management Therapeutics Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Companion
Animal Postoperative Pain Management Therapeutics Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com